Beate Gericke

Summary

Affiliation: University of Potsdam
Country: Germany

Publications

  1. ncbi request reprint Influence of hormone replacement therapy on proteomic pattern in serum of postmenopausal women
    Beate Gericke
    Institute of Nutritional Science, University Potsdam, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    Maturitas 51:334-42. 2005
  2. pmc Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
    Beate Gericke
    Department of Physiology and Pathophysiology, Institute of Nutritional Science, University of Potsdam, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    BMC Cancer 5:133. 2005
  3. doi request reprint Structural modifications of serum transthyretin in rats during protein-energy malnutrition
    Andrea Henze
    University of Potsdam, Institute of Nutritional Science, Department of Physiology and Pathophysiology, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    Rapid Commun Mass Spectrom 22:3270-4. 2008
  4. pmc Alteration of transthyretin microheterogeneity in serum of multiple trauma patients
    Beate Gericke
    Department of Physiology and Pathophysiology, Institute of Nutritional Science, University of Potsdam
    Biomark Insights 2:299-306. 2007
  5. ncbi request reprint Peptide and protein profiles in serum and follicular fluid of women undergoing IVF
    Florian J Schweigert
    Institute of Nutritional Science, University of Potsdam, Potsdam Rehbrucke, Germany
    Hum Reprod 21:2960-8. 2006
  6. ncbi request reprint Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer
    Jalid Sehouli
    Department of Obstetrics and Gynaecology, Charite, Humboldt University, Berlin, Germany
    Cancer Epidemiol Biomarkers Prev 12:1205-8. 2003
  7. doi request reprint Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer
    Lukas A Hefler
    Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 14:710-4. 2008
  8. ncbi request reprint Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression
    Dominique Koensgen
    Department of Obstetrics and Gynecology, Charite University Hospital, Campus Virchow, Berlin, Germany
    Gynecol Oncol 107:266-73. 2007
  9. ncbi request reprint Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study
    Alexander Mustea
    Department of Gynaecology and Obstetrics, Charite, Medical University of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Anticancer Res 27:1527-30. 2007
  10. ncbi request reprint Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
    Steffen Runz
    Tumor Immunology Programme D010, German Cancer Research Center, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    Gynecol Oncol 107:563-71. 2007

Collaborators

Detail Information

Publications21

  1. ncbi request reprint Influence of hormone replacement therapy on proteomic pattern in serum of postmenopausal women
    Beate Gericke
    Institute of Nutritional Science, University Potsdam, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    Maturitas 51:334-42. 2005
    ..Proteomics approaches to cardiovascular biology and disease hold the promise of identifying specific proteins and peptides or modification thereof to assist in the identification of novel biomarkers...
  2. pmc Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
    Beate Gericke
    Department of Physiology and Pathophysiology, Institute of Nutritional Science, University of Potsdam, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    BMC Cancer 5:133. 2005
    ..The main aim of the study was therefore to characterize differences in microheterogeneity between ascitic fluid and plasma of women affected with ovarian cancer and to evaluate the tumor site as the possible source of TTR...
  3. doi request reprint Structural modifications of serum transthyretin in rats during protein-energy malnutrition
    Andrea Henze
    University of Potsdam, Institute of Nutritional Science, Department of Physiology and Pathophysiology, Arthur Scheunert Allee 114 116, D 14558 Nuthetal, Germany
    Rapid Commun Mass Spectrom 22:3270-4. 2008
    ..Such changes are probably induced by protein-energy malnutrition-driven oxidative stress and might be linked to alterations in protein function and stability...
  4. pmc Alteration of transthyretin microheterogeneity in serum of multiple trauma patients
    Beate Gericke
    Department of Physiology and Pathophysiology, Institute of Nutritional Science, University of Potsdam
    Biomark Insights 2:299-306. 2007
    ..It is speculated that TTR modification may well be the mechanism underlying the morphological manifestation of amyloidose or Alzheimer's diseases in patients surviving multiple trauma...
  5. ncbi request reprint Peptide and protein profiles in serum and follicular fluid of women undergoing IVF
    Florian J Schweigert
    Institute of Nutritional Science, University of Potsdam, Potsdam Rehbrucke, Germany
    Hum Reprod 21:2960-8. 2006
    ..Compositional changes reflect oocyte maturation and can be used as diagnostic markers. The aim of the study was to determine protein and peptide profiles in paired serum and follicular fluid samples from women undergoing IVF...
  6. ncbi request reprint Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer
    Jalid Sehouli
    Department of Obstetrics and Gynaecology, Charite, Humboldt University, Berlin, Germany
    Cancer Epidemiol Biomarkers Prev 12:1205-8. 2003
    ..This allele seems to play an additional role in the occurrence of ovarian cancer and should be further investigated for screening and risk evaluation...
  7. doi request reprint Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer
    Lukas A Hefler
    Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria
    Clin Cancer Res 14:710-4. 2008
    ..To evaluate serum C-reactive protein (CRP) as prognostic variable in patients with epithelial ovarian cancer (EOC)...
  8. ncbi request reprint Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression
    Dominique Koensgen
    Department of Obstetrics and Gynecology, Charite University Hospital, Campus Virchow, Berlin, Germany
    Gynecol Oncol 107:266-73. 2007
    ..Expression of PAI-RBP1 (the new, approved gene symbol is SERBP1) has not been previously analyzed in human tumors. We present herein for the first time expression analysis of PAI-RBP1 in epithelial ovarian cancer...
  9. ncbi request reprint Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study
    Alexander Mustea
    Department of Gynaecology and Obstetrics, Charite, Medical University of Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Anticancer Res 27:1527-30. 2007
    ..For patients with OC, data are not available on EGFR gene mutation...
  10. ncbi request reprint Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM
    Steffen Runz
    Tumor Immunology Programme D010, German Cancer Research Center, Im Neuenheimer Feld 580, D 69120 Heidelberg, Germany
    Gynecol Oncol 107:563-71. 2007
    ..Given the emerging role of exosomes in tumor progression, we investigated whether cytoplasmic CD24 expression is correlated with the secretion of CD24 in exosomes...
  11. ncbi request reprint Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study
    Dominique Koensgen
    Department of Obstetrics and Genecology, Charite University Hospital, Campus Virchow Clinic, Berlin, Germany
    Cancer Chemother Pharmacol 62:393-400. 2008
    ..Because of its pharmacological properties, topotecan is a good adjunct to carboplatin in this setting, but its safety and efficacy remains to be defined...
  12. ncbi request reprint Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO
    Jalid Sehouli
    Department of Gynaecology and Gynaecologic Oncology, Charité Virchow University Hospital, Augustenburger Platz 1, 13353 Berlin, Germany
    Cancer Chemother Pharmacol 61:243-50. 2008
    ..To study the toxicity and efficacy of weekly paclitaxel and carboplatin (PC-W) in women with primary ovarian cancer..
  13. ncbi request reprint Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer
    Lukas A Hefler
    Department of Obstetrics and Gynecology and Core Unit for Medical Statistics and Informatics, Medical University of Vienna, Austria
    Clin Cancer Res 13:898-901. 2007
    ..Gene polymorphisms within the gene encoding VEGF were shown to be independently associated with an adverse outcome in various malignancies. No data are available for ovarian cancer...
  14. ncbi request reprint Vascular endothelial growth factor gene polymorphisms in ovarian cancer
    Stephan Polterauer
    Department of Obstetrics and Gynecology, Medical University of Vienna, A 1090 Vienna, Wahringer Gurtel 18 20, Austria
    Gynecol Oncol 105:385-9. 2007
    ..No data have been reported in ovarian cancer...
  15. ncbi request reprint Polymorphism of IL-1alpha, IL-1beta and IL-10 in patients with advanced ovarian cancer: results of a prospective study with 147 patients
    Elena Ioana Braicu
    Department of Gynecology and Obstetrics, Charite Campus Virchow Klinikum, Charité Medical University of Berlin, Germany
    Gynecol Oncol 104:680-5. 2007
    ..Interleukin 1 (IL-1) and IL-10 are critically involved in tumorigenesis. We investigated polymorphisms of IL-1 and IL-10 genes in patients with ovarian cancer (OC)...
  16. ncbi request reprint Expression of IL-10 in patients with ovarian carcinoma
    Alexander Mustea
    Charite, Department of Obstetrics and Gynecology, Medical University Berlin, D 13353 Berlin, Germany
    Anticancer Res 26:1715-8. 2006
    ..The aim of this study was to determine whether the level of IL-10 in the serum and ascites was associated with the prognosis of advanced ovarian cancer (OC)...
  17. pmc Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy
    Radoslav Chekerov
    Department of Obstetrics and Gynecology, Charite University Hospital, Campus Virchow, Berlin, Germany
    Neoplasia 8:38-45. 2006
    ..The aim of this study was to evaluate the expression of topoisomerase IIalpha (TOP2A) in epithelial and stromal cells of ovarian cancer...
  18. ncbi request reprint The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer
    Peng ming Sun
    Department of Obstetrics and Gynecology, Peking University People s Hospital, Peking University Health Science Center, Xizhimen South Street No 11, 100044 Beijing, PR China
    Eur J Obstet Gynecol Reprod Biol 130:249-57. 2007
    ..The potential value of them as indicators for chemotherapy in ovarian cancer cells was also studied...
  19. ncbi request reprint Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells
    Pengming Sun
    Department of Obstetrics and Gynecology, Peking University People s Hospital, Peking University Health Science Center, 100044, Beijing, People s Republic of China
    J Mol Med (Berl) 83:457-67. 2005
    ..032; 95% CI, 1.27-6.06). Based on our results, ERRs may play an important role in ovarian cancer. hERRalpha may represent a biomarker of poor prognosis, and hERRgamma may be a new therapeutic target in ovarian cancer...
  20. ncbi request reprint Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients
    Jalid Sehouli
    Department of Obstetrics and Gynecology, Charite, Berlin, Germany
    Anticancer Res 24:1223-9. 2004
    ..The stage at time of diagnosis is the only prognostic factor that is unequivocally related to survival. Other prognostic factors have not been well defined and are discussed in the literature controversially...
  21. ncbi request reprint Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study
    Jalid Sehouli
    Charite, Department of Obstetrics and Gynaecology, Humboldt University, Augustenburger Platz 1, D 13353 Berlin, Germany
    Anticancer Res 23:1115-8. 2003
    ..CA-125 is the most important tumor marker in epithelial ovarian cancer. Due to its low specificity, a combination with CASA may improve the clinical discrimination between benign and malignant adnexal masses...